Neuraxis Inc (NRXS) Stock AnalysisNRXSStock AnalysisNeuraxis Inc

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Neuraxis Inc (NRXS) is a good buy right now, primarily due to its significant revenue growth of 116% year-over-year in Q2 2026, reaching $1.9 million, and a gross margin of 86.42%, indicating strong profitability potential. However, the main risk is the current RSI of 30.094, suggesting the stock is oversold and may face short-term volatility.